NEW YORK (dpa-AFX Broker) - The US bank JPMorgan has left its rating for Evonik at "Overweight" with a target price of 25 euros. There are signs of a further recovery in demand in the second quarter, which still leaves room for the consensus, analyst Chetan Udeshi wrote on Wednesday evening following the report on the first quarter./ag/ngu

Publication of the original study: 08.05.2024 / 22:45 / BST

First dissemination of the original study: 09.05.2024 / 00:15 / BST

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------